Genprex signs exclusive license for diabetes gene therapy with University of Pittsburgh

Genprex, Inc.

Exclusive worldwide license for gene therapy using MafB promoter to drive Pdx1 and MafA for Type 1 and Type 2 diabetes.
Preclinical NHP data showed statistically significant decreases in insulin requirements (p<0.001), increased c-peptide (p<0.05), improved glucose tolerance.
Milestone payments up to ~$4.225M plus royalties; technology co-developed by Dr. George Gittes.
Expands existing diabetes gene therapy portfolio; AAV vector delivered via endoscopy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Genprex, Inc. entered into Exclusive License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy (effective 2023-07-14).

Action: entry
Agreement: license
Counterparty: University of Pittsburgh - Of the Commonwealth System of Higher Education
Value: Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy
Effective: 2023-07-14

Exact text from the filing

On July 14, 2023, Genprex, Inc. (“Genprex”) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (“UP”) entered into an Exclusive License Agreement (the “UP License Agreement”), pursuant to which UP granted to Genprex a worldwide, exclusive license under certain patents and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for both Type 1 and Type 2 diabetes using a MafB promoter to drive expression of the Pdx1 and MafA transcription factors.

View on SEC.gov

Browse all material agreements →

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-020093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.